lenalidomide,rituximab
biogen,roche
['relevance trial', 'lymsm', 'cml', 'valent ,(-prevalent)']
long-term follow-up from relevance trial does suggest that r^2 is equivalent to r-chemo (although definitely different toxicity profiles), although concedes that r-chemo may be preferred given possibility for cure (15-yr data to be presented at #17icml). #lymsm 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈